ICCC (ImmuCell) Debt-to-Asset : 0.27 (As of Jun. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

ICCC ImmuCell Corp ICCC
51 GF Score
Price $9.95
GF Value $6.94
Valuation Significantly Overvalued
! 1 Warning Sign
View Full Analysis

What is ImmuCell Debt-to-Asset?

ImmuCell ICCC -1.11% 51 Debt-to-Asset is 0.27 as of Jun. 2026. GuruFocus rates ICCC with a GF Score™ of 51/100 and a GF Value™ of $6.94 (Significantly Overvalued). The stock has 1 warning sign investors should review.

ImmuCell's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Jun. 2026 was $1.63 Mil. ImmuCell's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Jun. 2026 was $10.82 Mil. ImmuCell's Long-Term Debt & Capital Lease ObligationTotal Assets for the quarter that ended in Jun. 2026 was $46.63 Mil. ImmuCell's debt to asset for the quarter that ended in Jun. 2026 was 0.27.

ImmuCell  (NAS:ICCC) Debt-to-Asset Explanation

In the calculation of Debt-to-Asset, we use the total of Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation divided by Total Assets.

ImmuCell Debt-to-Asset Related Terms

ImmuCell Debt-to-Asset Historical Data

* Premium members only.

The historical data trend for ImmuCell's Debt-to-Asset can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

ImmuCell Debt-to-Asset Chart

ImmuCell Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Debt-to-Asset
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.23 0.28 0.38 0.34 0.31

ImmuCell Quarterly Data
Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26 Jun26
Debt-to-Asset Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.31 0.30 0.31 0.29 0.27

ICCC vs ATRA, ALDX, RLYB: Debt-to-Asset Comparison

For the Biotechnology subindustry, ImmuCell's Debt-to-Asset, along with its competitors' market caps and Debt-to-Asset data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

ImmuCell Debt-to-Asset vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, ImmuCell's Debt-to-Asset distribution charts can be found below:

* The bar in red indicates where ImmuCell's Debt-to-Asset falls into.


ICCC
51GF Score
ImmuCell Corp ICCC
Debt-to-Asset is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

ImmuCell Debt-to-Asset Calculation

Debt to Asset measures the financial leverage a company has.

ImmuCell's Debt-to-Asset for the fiscal year that ended in Dec. 2025 is calculated as

Debt-to-Asset=Total Debt / Total Assets
=(Short-Term Debt & Capital Lease Obligation + Long-Term Debt & Capital Lease Obligation) / Total Assets
=(1.696 + 11.499) / 42.532
=0.31

ImmuCell's Debt-to-Asset for the quarter that ended in Jun. 2026 is calculated as

Debt-to-Asset=Total Debt / Total Assets
=(Short-Term Debt & Capital Lease Obligation + Long-Term Debt & Capital Lease Obligation) / Total Assets
=(1.628 + 10.819) / 46.63
=0.27

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Debt-to-Asset →
What does a Debt-to-Asset of 0.27 mean?
ImmuCell (ICCC) has a Debt-to-Asset of 0.27 as of Jun. 2026. Debt-to-asset ratio represents the ratio of total debt to total assets. View historical data on ImmuCell and its competitors.
Is ImmuCell's Debt-to-Asset too high?
ImmuCell's current Debt-to-Asset is 0.27. Overall, ImmuCell has a GF Score™ of 51/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does ImmuCell's Debt-to-Asset compare to ATRA and ALDX?
ImmuCell's Debt-to-Asset of 0.27 can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Debt-to-Asset for a Biotechnology company?
A good Debt-to-Asset depends on the Biotechnology industry context. However, Debt-to-Asset should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Debt-to-Asset mean?
A high Debt-to-Asset can signal that a stock is expensive relative to its fundamentals. Debt-to-asset ratio represents the ratio of total debt to total assets. View historical data on ImmuCell and its competitors. ImmuCell's current Debt-to-Asset is 0.27. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is ImmuCell stock overvalued right now?
Based on GuruFocus' analysis, ImmuCell (ICCC) is currently considered Significantly Overvalued. The stock's GF Value™ is $6.94, compared to a current price of $9.95 — trading 43.4% above its estimated fair value. The current Debt-to-Asset is 0.27. ImmuCell's overall GF Score™ is 51/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Debt-to-Asset calculated?
Debt-to-Asset is calculated from a company's financial statements. For ImmuCell (ICCC), the current Debt-to-Asset is 0.27 as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is ImmuCell (ICCC) Overvalued in 2026?

Based on GuruFocus' analysis, ImmuCell stock appears to be overvalued. The current stock price of $9.95 is trading 43.4% above its estimated GF Value™ of $6.94. GuruFocus considers ImmuCell to be Significantly Overvalued.

Key valuation signals for ICCC:

  • Debt-to-Asset: 0.27
  • GF Value™: $6.94 vs. price of $9.95 (43.4% above fair value)
  • GF Score™: 51/100 with 1 warning sign

No single metric tells the full story. See the ICCC stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

ImmuCell Business Description

Other Exchanges IUL:Germany
Address 56 Evergreen Drive, Portland, ME, USA, 04103
ImmuCell Corp is an animal health biologics company focused on the development, manufacture, and commercialization of products intended to improve the survivability, health, and long-term performance of neonatal dairy and beef calves. Its product, First Defense, utilizes hyperimmunized bovine colostrum to provide pathogen-specific antibodies and other bioactive components. First Defense is designed to provide Immediate Immunity through orally delivered antibodies against the principal viral and bacterial causes of neonatal calf diarrhea (scours), including Escherichia coli (E.coli), bovine coronavirus, and bovine rotavirus. It has two operating segments: Scours and Mastitis. It derives the majority of the revenue from the Scours segment that consists of the First Defense product line.
51GF Score

Get the complete analysis for ICCC

Debt-to-Asset is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$9.95
Price
$6.94
GF Value